Nanoparticle contrast agents for earlier breast cancer detection
Nanoparticle contrast agents for earlier breast cancer detection
批准号:
10392420
负责人:
David Peter Cormode
金额:
$43.94万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2024-04-30
关键词:
AddressAffectBehaviorBiologicalBloodBlood CirculationBody Weights and MeasuresBreastBreast Cancer DetectionBreast Cancer Early DetectionBreast Cancer ModelBreast Cancer Risk FactorBreast Cancer TreatmentCaliberClaustrophobiasClinicalClinical ChemistryClinical DataContrast MediaDataDetectionDigital MammographyDiseaseDrug KineticsEarly DiagnosisEffectivenessElementsEncapsulatedEquipmentExcretory functionFormulationGoldHigh Risk WomanHistologyHourHypersensitivityImageIn VitroInductively Coupled Plasma Mass SpectrometryIodineKidneyKidney FailureLibrariesMagnetic Resonance ImagingMalignant NeoplasmsMammographic screeningMammographyMethodsMinorNanosphereNanostructuresOrganPatientsPolymersPopulationProceduresPropertyPublishingRoentgen RaysSafetyScanningScreening procedureSilverSolubilitySpecificityStructureSystemTechniquesTestingTimeToxic effectTransgenic ModelTranslationsVariantWomananti-cancerbasebiodegradable polymerbiomaterial compatibilitycancer imagingcancer typecomparativecontrast enhancedcostcost effectivedesignflexibilityhigh riskhigh risk populationhydrophilicityimaging potentialimprovedin vitro Assayin vivomalignant breast neoplasmmortalitynanocrystalnanomaterialsnanoparticlenovelpolyphosphazenepreventpublic health relevancescreeningscreening programsilver sulfidesmall moleculetooltumor
中文摘要
项目总结
到目前为止,乳腺癌是最常见的癌症类型,是女性第二致命的癌症。
早期发现乳腺癌的乳房X光检查项目很普遍。乳房X光摄影
筛查可以降低乳腺癌的死亡率,而且具有成本效益。然而,有消息称,
乳房致密的女性(约占女性的10%)乳房X光检查不是很有效,敏感度为30%-
60%。此外,与较低的肿瘤检测机会无关,乳房致密的女性处于
患乳腺癌的风险更高。因此,为了降低这一人群中乳腺癌的死亡率,更好地
筛选技术是必要的。
双能量乳房X光检查是最近出现的一种高度敏感和特异的技术
检测乳房致密的女性的癌症。一种用于双能量乳房X光摄影的造影剂,可以
对于乳房致密的女性以及特定的高危人群,确定肿瘤是非常有益的。
人口。目前已有的碘基造影剂药代动力学较差,肿瘤发生率低
在许多患者中有积聚和禁忌症。而其他技术,如对比度增强
MRI可用于乳房致密女性筛查,费用高实用障碍阻碍
这些技术的使用。
在此,我们建议开发新型的、可生物降解的银基纳米颗粒(SBNP),以实现安全检测
乳腺癌风险较高的患者中的肿瘤。我们已经发现,银是一种能产生
双能量乳房X光摄影的卓越对比度一种新的乳房X光摄影技术,两幅图像
在不同的X射线能量下获得。我们已经找到了使纳米颗粒稳定和
生物相容。我们选择了一种相对简单但灵活的纳米颗粒设计,以改进
翻译的可能性。纳米颗粒应该会在肿瘤中迅速积聚,使它们
在乳房X光检查中很明显,然后逐渐分解成肾脏排泄的成分。这
该提案解决了在癌症中使用纳米颗粒的一个关键挑战:排泄。作为该提案的一部分
我们将开发一种可生物降解的载体系统,该系统可以将小的、高度亲水的纳米颗粒输送到
肿瘤,在分解和肾脏排泄之前。这一运输系统可能会产生广泛的影响,因为它可能
可应用于多种不同的纳米颗粒类型和抗癌方法。
英文摘要
PROJECT SUMMARY
Breast cancer is by far the most common type of cancer and is the second most deadly cancer in women.
Breast cancer mammography screening programs for early detection are widespread. Mammography
screening reduces mortality from breast cancer and is cost-effective. However, it has emerged that
mammography is not very effective in women with dense breasts (about 10% of women), with sensitivity of 30-
60%. Moreover, independent of the lower chance of tumor detection, women with dense breasts are at a
higher risk of breast cancer. Therefore to reduce mortality from breast cancer in this population, better
screening techniques are needed.
Dual-energy mammography has recently emerged as a technique that is highly sensitive and specific for
detecting cancer in women with dense breasts. A contrast agent for dual-energy mammography that can
identify tumors would be highly beneficial in women with dense breasts, as well as in selected high-risk
populations. Currently available iodine-based contrast agents have poor pharmacokinetics, low tumor
accumulation and are contraindicated in many patients. While other techniques such as contrast-enhanced
MRI can be used for screening women with dense breasts, the high costs and practical obstacles prevent the
use of those techniques.
We herein propose to develop novel, biodegradable silver-based nanoparticles (SBNP) to allow safe detection
of tumors in patients at higher risk of breast cancer. We have found that silver is an element that produces
excellent contrast in dual-energy mammography a new variation of mammography where two images are
acquired at different x-ray energies. We have found methods that make the nanoparticles stable and
biocompatible. We have chosen a comparatively simple, yet flexible nanoparticle design in order to improve
the likelihood of translation. The nanoparticles should quickly accumulate in tumors, rendering them
conspicuous on mammography, before gradually breaking down into their components for renal excretion. This
proposal addresses a key challenge in the use of nanoparticles in cancer: excretion. As part of this proposal
we will develop a biodegradable carrier system that can deliver small, highly hydrophilic nanoparticles to
tumors, before breakdown and renal excretion. This carrier system could have a broad impact, since it could
be applied to numerous different nanoparticle types and anti-cancer approaches.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/acsami.2c06190
发表时间:
2022-08-03
期刊:
ACS APPLIED MATERIALS & INTERFACES
影响因子:
9.5
作者:
[Nieves, Lenitza M., Dong, Yuxi C., Rosario-Berrios, Derick N., Mossburg, Katherine, Hsu, Jessica C., Cramer, Gwendolyn M., Busch, Theresa M., Maidment, Andrew D. A., Cormode, David P.]
通讯作者:
Cormode, David P.
Silver chalcogenide nanoparticles: a review of their biomedical applications.
银樱桃剂纳米颗粒:对其生物医学应用的综述。
DOI:
10.1039/d0nr03872e
发表时间:
2021-12-02
期刊:
Nanoscale
影响因子:
6.7
作者:
[Nieves LM, Mossburg K, Hsu JC, Maidment ADA, Cormode DP]
通讯作者:
Cormode DP
DOI:
10.1021/acsami.1c18941
发表时间:
2021-12-15
期刊:
ACS applied materials & interfaces
影响因子:
9.5
作者:
[Hsu JC, Du Y, Sengupta A, Dong YC, Mossburg KJ, Bouché M, Maidment ADA, Weljie AM, Cormode DP]
通讯作者:
Cormode DP
DOI:
10.1039/d0nr05489e
发表时间:
2021-01-08
期刊:
Nanoscale
影响因子:
6.7
作者:
[Nieves LM , Hsu JC , Lau KC , Maidment ADA , Cormode DP ]
通讯作者:
Cormode DP
Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography
-
批准号:10459234
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:David Peter Cormode
-
依托单位:
Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma
-
批准号:10397989
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9925060
-
项目类别:
-
资助金额:$52.44万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9815637
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable gold nanoparticles as contrast agents for CT
-
批准号:9341531
-
项目类别:
-
资助金额:$22.3万
-
财政年份:2017
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9899293
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9242691
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8703435
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8842600
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8490376
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8678912
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:7952549
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8120348
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8474382
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
海外基金